Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) Versus VAC Alternating With Vincristine and Irinotecan (VI) for Patients With Intermediate-Risk Rhabdomyosarcoma (RMS)

NCT00354835 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT00354835
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00354835 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) Versus VAC Alternating With Vincristine and Irinotecan (VI) for Patients With Intermediate-Risk Rhabdomyosarcoma (RMS)
Lead sponsor
Children's Oncology Group
Phase
Phase 3
Overall status
Completed
Start date
December 26, 2006
Completion date
December 31, 2022
Enrollment
481 (actual)
Sites
226

Conditions

As the registry lists them; a condition with its own page is linked.

adult rhabdomyosarcoma, childhood alveolar rhabdomyosarcoma, childhood botryoid-type embryonal rhabdomyosarcoma, childhood embryonal rhabdomyosarcoma, localized childhood soft tissue sarcoma, rhabdomyosarcoma, sarcoma, stage i adult soft tissue sarcoma ajcc v7, stage ii adult soft tissue sarcoma ajcc v7, stage iii adult soft tissue sarcoma ajcc v7